A Comparative Study to Understand the Add on Effect of Oral retention With Saptachadadi kashaya followed by application of Mahatiktaka Ghrita along with the Standard treatment in patients with Mouth Ulcers caused by Chemotherapy.

Effect of Add-On Therapy With Saptachadadi Kwatha Gandoosha Followed By Mahatiktakam Ghrita Pratisarana In Chemotherapy Induced Oral Mucositis PatientsUnder Standard of Care.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/01/022928

Enrollment

Registered

2020-01-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K123- Oral mucositis (ulcerative)

Interventions

Intervention1: 1)Mouthwash 2)Gandoosha 2)Pratisarana : 1)Mouthwash with Chlorhexadine 3 times a day (6 hourly),for 14 days. 2)Gandoosha with Sapthachadadi Kwatha 5 times a day-(1hour spacing

Eligibility

Inclusion criteria

Inclusion criteria: Chemotherapy induced Oral Mucositis subjects. Subjects with written informed consents. Grade 2-3(WHO SCALE)

Exclusion criteria

Exclusion criteria: Cancer therapy other than chemotherapy undergoing patients. Age- below 18 years Patients with Oral cancers,Trismus or any other pre diagnosed conditions as HIV, Syphyllis ,Bechets disease.

Design outcomes

Primary

Measure	Time frame
1)WHO scale for the assessment of Oral Mucositis. 2)VAS scale for the assessment of pain in Oral Mucositis. Timepoint: 1)Before intervention - 0th day 2)After intervention - 15th day	—

Secondary

Measure	Time frame
Karnofsky Performance Scale for the assessment of quality of life. Timepoint: 1)Before intervention - 0th day 2)After intervention - 15th day	—

Countries

India

Contacts

Public ContactDr James Chacko

Amrita School of Ayurveda

drjames.2008@rediffmail.com9495191191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026